Considering the IL-6 overproduction observed in RA, one of the biologic DMARDs used successfully for its treatment is tocilizumab, a humanized anti-IL-6 receptor (anti-IL-6R) monoclonal antibody designed to block IL-6 signaling [10]. Here, IL6 is linked to rheumatoid arthritis.